OCS
NASDAQ HealthcareOculis Holding AG - Ordinary shares
Biotechnology
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
๐ Market Data
| Price | $27.48 |
|---|---|
| Volume | 158,707 |
| Market Cap | 1.59B |
| Beta | 0.210 |
| RSI (14-Day) | 52.4 |
| 200-Day MA | $22.12 |
| 50-Day MA | $27.06 |
| 52-Week High | $30.68 |
| 52-Week Low | $16.00 |
| Forward P/E | -12.80 |
| Price / Book | 6.37 |
๐ฏ Investment Strategy Scores
OCS scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ฐ Dividend Daddy (49/100) โ this strategy High dividend yield + low volatility.
Lowest fit among scored strategies: ๐ Moon Shot (19/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find OCS in your text
Paste any article, transcript, or post โ the tool will extract OCS and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.